Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. - Wikidata - awgldk - TriplyDB

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

http://www.wikidata.org/entity/Q35780831

about

Down syndrome and leukemia: insights into leukemogenesis and translational targets Genomic landscape of megakaryopoiesis and platelet function defects The biology of pediatric acute megakaryoblastic leukemia Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update Selective inhibition of the kinase DYRK1A by targeting its folding process GATA factor mutations in hematologic disease.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Riquiqui and minibrain are regulators of the hippo pathway downstream of Dachsous.Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS)Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3 The role of the chromatin assembly complex (CAF-1) and its p60 subunit (CHAF1b) in homeostasis and disease Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia.Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21 The calcineurin-NFAT pathway negatively regulates megakaryopoiesis.Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.Trisomy 21 consistently activates the interferon response.The impact of trisomy 21 on foetal haematopoiesis.Haematopoietic development and leukaemia in Down syndrome.Stem and progenitor cell dysfunction in human trisomies.DYRK1A phoshorylates histone H3 to differentially regulate the binding of HP1 isoforms and antagonize HP1-mediated transcriptional repression.Evolution of myeloid leukemia in children with Down syndrome.DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes.Screening of potential biomarkers for prenatal diagnosis of trisomy 21.AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders.Cohesin Mutations in Myeloid Malignancies.BMP meets AML: induction of BMP signaling by a novel fusion gene promotes pediatric acute leukemia.DYRK1A in Down syndrome: an oncogene or tumor suppressor?The impact of trisomy 21 on early human hematopoiesis.Apoptosis in Down's syndrome: lessons from studies of human and mouse models.Rodent models in Down syndrome research: impact and future opportunities.Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors.A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons.

P2860

Q26770335-B75F50D0-DD3D-4F57-B78B-051C18A6C232 Q26770869-1EB9EF9F-7EE7-4976-9B48-5863DB733325 Q26799478-17DF2FA2-DB2B-44AD-B31F-D3E6130FD97E Q28079980-764AF6F6-135B-434A-B541-DA505596AEDB Q28834235-3AD26216-4E81-4667-976F-39C36CAFFD62 Q33439175-F11A605D-1829-4A06-8B8A-47F7B7ED785C Q33698398-C5B08B08-209E-4D1A-9397-C84BD32CA858 Q34149201-210FFEE8-E8B4-42C0-93D5-380747BCD91B Q34849602-B537842E-9897-49F6-A85D-8A43CB31CAD3 Q35005153-5956DB51-22A5-4574-AE43-DC47D19E3F36 Q35283950-C6B0A085-DEF6-449E-A0EE-6E9AD08B572D Q35606539-0C64AA88-8E16-40DD-A476-66EE87187668 Q35640834-6D378323-32D9-4C6F-9ECD-37DD36FDAB49 Q35890006-75BB0F3C-FBEC-4477-AE91-030B37E0FDC2 Q36280034-B80E81C6-D1F5-44B8-9DD0-399ED2462EEC Q36340868-0C49E07D-16EE-4351-A116-47173055B2D8 Q36378400-E4FAECFE-9154-4EBC-A822-214C1E3AF6BE Q36378527-5CAA269F-2496-48CE-A1E1-03603722165B Q36779438-177A575F-F5F7-4160-8315-6AF799CDAE3D Q37083967-DE9F97E4-7090-4FF8-AE64-464A6747CD56 Q37215179-3A5603CC-0EC7-4D2A-8FA0-627E1B868C69 Q37235217-AB090914-D023-48B9-B7A6-CF6BA2237C61 Q38127994-177828A0-99FC-489D-A62F-EC7813E04121 Q38243161-8F741EA2-FAA9-404B-98A0-C127BDA91AF0 Q38292512-744A7EA8-28EA-4DEF-B25F-24366CAF64EC Q38307139-5B9F8236-EEFF-41CA-B7A2-6D5EDAB1D32B Q38748238-0ABEFBF7-1181-4A22-B529-B2D60E2A0CE5 Q38866748-B9115981-72BA-4253-A3B8-E5F7D650A4E4 Q39005643-C26CD33A-8387-4A79-A4A0-80229CA8AADC Q39064384-8F48BF9F-F01C-4960-B9D5-AD4248C7D066 Q39199734-9A3C023E-69D1-4EDF-B4E1-60BCA0020947 Q39350289-BF45787D-C3C9-4127-8F1E-406298DB9081 Q39381849-AD2B5FA9-9077-45CB-820B-7BCE8F59D163 Q41547520-7C626CC0-CBC5-414C-A6DF-8E3EE3F564C1 Q41580184-B583098D-5AD3-4852-B093-325B2A92934A Q43231880-2E3AF8AE-176E-4412-A159-D991CC4A46F1 Q43723779-1D32833A-97A1-419E-8041-5882416ABA43 Q46193918-AFC14A1B-EABE-4926-9BC6-6A87585B8818 Q49757490-1A03B39F-18A6-4B02-BA54-A1A30E565AA6 Q50307045-CDA1FF6F-6A17-45D0-B782-0FEAC2DFC917

P2860

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

http://www.wikidata.org/entity/Q35780831

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Increased dosage of the chromo ...... murine model of Down syndrome.

@ast

Increased dosage of the chromo ...... murine model of Down syndrome.

@en

type

label

Increased dosage of the chromo ...... murine model of Down syndrome.

@ast

Increased dosage of the chromo ...... murine model of Down syndrome.

@en

prefLabel

Increased dosage of the chromo ...... murine model of Down syndrome.

@ast

Increased dosage of the chromo ...... murine model of Down syndrome.

@en

P1433

Q35780831-3BF1F9F6-58B2-4B64-A721-9814E9CC34F0

P1476

Q35780831-03CC1038-8883-431F-A5A3-10E39956D949

P2093

Q35780831-09D57544-12AC-4332-82CC-069F121475F7

Q35780831-4CB47A66-0646-48C8-AA6E-862741F59886

Q35780831-777B3CDA-CB00-40CD-8622-5C9512C20D66

Q35780831-B49E0029-04AA-407B-AC9E-E72857AB69A7

Q35780831-C0BAA836-9DA0-4A39-B2EB-7186FCD4BBC4

Q35780831-EA29CE90-720E-4E7B-BC39-8A60D82DA763

P2860

Q35780831-04F50341-6167-4F20-922C-F527DFA330A9

Q35780831-0AF16E8C-60A9-4B6E-BE8C-A1D24D083DC1

Q35780831-0FB36491-D17D-48A8-94B4-A1683ECB0DE4

Q35780831-0FB741A6-2A6A-439E-B355-80A7EC9FBE6B

Q35780831-12706D00-2960-4DED-A129-179FA6369FF8

Q35780831-15C1D334-A79A-4473-92D0-422CDB8D1DCF

Q35780831-1B457659-F58D-4AA2-A698-38FF99349964

Q35780831-20300610-0702-47B3-91D5-AD7E38B0D5D6

Q35780831-21D6CB02-5E9B-4C7E-A0B4-C15E31BE164C

Q35780831-2BFCBD7B-4AD2-48FB-96FB-B630DA85349B

P304

Q35780831-1C2D9D3C-EF5D-41ED-9711-FC4FB9D16883

P31

Q35780831-A7C12CB4-08F7-4D56-80D4-2642C53AAC04

P356

Q35780831-82543B24-DDD0-48FD-B41A-39C9C8831DFD

P407

Q35780831-5061181A-C520-4EAF-93C1-20A5257F048F

P433

Q35780831-C5ABC7DF-EDF1-4BE1-8F62-5E411F752463

P478

Q35780831-25EBD21A-8F2C-439D-9E93-8F25310E047D

P50

Q35780831-9B2BEDC0-9D4E-4F52-B518-E71B8D7C71F7

P577

Q35780831-1F5C3613-5C6A-409B-8FCF-A8AD875F3AAA

P5875

Q35780831-99CC7D1C-ECA8-4823-9465-1D4EA817E95A

P698

Q35780831-E33F1A2B-E4AB-47AE-ABC2-F217B63A88A2

P921

Q35780831-5AD13338-666A-4727-84CA-B21A5A016BE5

P932

Q35780831-923A305F-0B77-436F-86A8-C588A95170C0

P356

P1433

Journal of Clinical Investigation

P1476

Increased dosage of the chromo ...... murine model of Down syndrome

@en

P2093

Gina Kirsammer

http://www.w3.org/2001/XMLSchema#string

John D Crispino

http://www.w3.org/2001/XMLSchema#string

Lauren Diebold

http://www.w3.org/2001/XMLSchema#string

Meghan Bliss-Moreau

http://www.w3.org/2001/XMLSchema#string

Sandeep Gurbuxani

http://www.w3.org/2001/XMLSchema#string

Timothy Chlon

http://www.w3.org/2001/XMLSchema#string

P2860

The selectivity of protein kinase inhibitors: a further update

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1

The oncogenic role of the ETS transcription factors MEF and ERG

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines

Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome

ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells

Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice

Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.

P304

948-962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI60455

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Sébastien Malinge

P577

2012-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221851046

http://www.w3.org/2001/XMLSchema#string

P698

22354171

http://www.w3.org/2001/XMLSchema#string

P921

P932

3287382

http://www.w3.org/2001/XMLSchema#string